Committed to Treatments and Cures of Alzheimer's Disease
Alzamend Neuro, Inc.
Alzamend Neuro® is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease, Bipolar disorder, Major Depressive Disorder ("MDD") and Post-Traumatic Stress Disorder ("PTSD"). Our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ Million Americans suffering from these debilitating diseases. Our current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and ALZN002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.
Pipeline / Learn More
Watch: Alzheimer’s & the Brain
We are driven by the belief that strong support of research is the foundation for true innovation.
Publications
Recently Published Articles
AL002 – An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid-β
AL001 – Comparing the effect of the novel ionic cocrystal of lithium salicylate proline (LISPRO) with lithium carbonate and lithium salicylate on memory and behavior in female APPswe/PS1dE9 Alzheimer's mice
AL002 – Dendritic and Langerhans cells respond to Aβ peptides differently: implication for AD immunotherapy.
6.5 million
The number of Americans projected currently living with Alzheimer's disease in 2022
Press Releases
- Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
- Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
- Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
- Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
- Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions